Want to see TSE:ASG full AI Analyst Report?
Aurora Spine (ASG) AI Stock Analysis
Aurora Spine
(TSXV:ASG)
The score is held back primarily by continued net losses and negative returns despite improving cash flow, alongside bearish technicals with the stock trading below all major moving averages and negative MACD. Valuation is also constrained by the negative P/E, which reflects loss-making operations and adds risk.
Aurora Spine (ASG) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 8.98M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.85K
- Price to Earnings (P/E)
- -5.4
- Beta (1Y)
- 0.55
- Revenue Growth
- -5.42%
- EPS Growth
- -5.37%
- Country
- Canada
- Employees
- 13
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Aurora Spine Business Overview & Revenue Model
Company Description
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within th...
Aurora Spine Earnings Call Summary
The earnings call highlights significant revenue growth, product success, and gross margin improvements. However, these positives are tempered by increased operating expenses, a fourth-quarter EBITDAC decline, and a sustained net loss. While Aurora's product portfolio shows promise, financial challenges remain.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Aurora Spine Fourth Quarter and Fiscal Year 2024 Results Conference Call, a comprehensive financial and operational overview was provided. The company reported a 21% increase in revenue for 2024, reaching $17.56 million compared to $14.52 million in 2023. Notably, the SiLO-TFX system saw a remarkable 135% increase in revenue, contributing significantly to this growth. The ZIP series, particularly ZIP-51, experienced a 69% increase in sales. Gross margins improved to 60.5% for the fiscal year, up from 56.5% in 2023, attributed to the focus on proprietary products and better pricing strategies. Operating expenses rose to $11.438 million, driven by increased sales personnel and training costs. EBITDAC for 2024 turned positive at $0.28 million, a significant improvement from a negative $0.31 million in 2023. Net loss for the year reduced to $1.003 million from $1.68 million in 2023. The company ended the quarter with $0.826 million in cash, and management expressed confidence in their capital structure to meet budgetary needs, focusing on profitability and continued growth with new product launches and clinical studies.
Aurora Spine Financial Statement Overview
Summary
Operational trend is improving (EBITDA slightly positive and operating/free cash flow positive since 2024), but profitability remains weak with persistent net losses and meaningfully negative ROE. Recent softness in 2026 TTM revenue and a sharp drop in free cash flow versus 2025 increase execution risk despite improving margins and manageable leverage.
Income Statement
44NeutralBalance Sheet
52NeutralCash Flow
57Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.38M | 18.37M | 17.56M | 14.52M | 14.88M | 10.54M |
| Gross Profit | 7.27M | 4.51M | 10.63M | 8.21M | 7.81M | 4.83M |
| EBITDA | 221.95K | 753.73K | 179.90K | -446.20K | -469.27K | -1.55M |
| Net Income | -1.21M | ― | -1.00M | -1.68M | -1.50M | -2.36M |
Balance Sheet | ||||||
| Total Assets | 8.92M | 10.39M | 11.67M | 11.99M | 10.12M | 10.56M |
| Cash, Cash Equivalents and Short-Term Investments | 362.04K | 895.08K | 775.62K | 766.83K | 423.40K | 3.17M |
| Total Debt | 2.17M | 3.54M | 3.67M | 3.65M | 2.97M | 2.55M |
| Total Liabilities | 6.10M | 6.58M | 7.28M | 6.69M | 5.81M | 4.99M |
| Stockholders Equity | 2.82M | 3.81M | 4.40M | 5.30M | 4.32M | 5.57M |
Cash Flow | ||||||
| Free Cash Flow | 308.34K | 419.97K | 266.47K | -1.41M | -2.43M | -2.85M |
| Operating Cash Flow | 838.15K | 933.42K | 904.33K | -935.06K | -1.56M | -2.13M |
| Investing Cash Flow | -602.15K | -553.13K | -484.32K | -479.13K | -873.21K | -720.61K |
| Financing Cash Flow | -407.58K | -307.96K | -361.22K | 1.76M | -318.15K | 4.31M |
Aurora Spine Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.15, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 40.80 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASG.
Aurora Spine Peers Comparison
Overall Rating
- TSE:ASG47Neutral
TSE:VPT46Neutral
TSE:TLT41.2Neutral
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:ASG | 47Neutral | CAD 8.98M | -5.36 | -34.32% | ― | -5.42% | -5.37% |
| TSE:VPT | 46Neutral | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:TLT | 41Neutral | CAD 55.89M | -12.68 | -130.04% | ― | -24.86% | 18.29% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ASG | Aurora Spine | 0.12 | -0.17 | -58.93% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:TLT | Theralase Technologies | 0.18 | -0.02 | -10.00% | |
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% |
Aurora Spine Corporate Events
Aurora Spine Gains Peer-Reviewed Support for ZIP Fusion System with 12-Month REFINE Data
PositiveAurora Spine announced that the 12-month results of its REFINE study on the ZIP MIS Interlaminar Fusion System have been published in the International Journal of Spine Surgery. The prospective, multicenter study followed patients with neurogenic cla...
Aurora Spine Revenue Falls as Sales Transition Weighs, But DEXA-C Demand Surges
NegativeAurora Spine reported second-quarter fiscal 2026 revenue of $3.66 million, down 18.7% year over year, as weaker demand in the pain market and lower SI joint product sales outweighed gains in cervical implants and biologics. Gross margin slipped to 60...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026